BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, June 20, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 25, 2021

View Archived Issues

KAT7 identified as a driver of cellular senescence

Read More

MediciNova initiates phase II trial of ibudilast in COVID-19 patients at risk of ARDS

Read More

First-in-human study evaluates EMB-02 for advanced solid tumors

Read More

In situ-gelling hydrogel with tunable properties for intranasal drug delivery to the brain

Read More

Hyper-IL-6 gene therapy stimulates axon regeneration and functional recovery after SCI in mice

Read More

Antibody-drug conjugates with new PNU-159682 derivatives show anticancer efficacy in vivo

Read More

Orladeyo approved in Japan for the prophylactic treatment of hereditary angioedema

Read More

Qilu Regor Therapeutics patents MALT1 inhibitors

Read More

Lundbeck discloses new antidepressants

Read More

Galecto Biotech identifies new LGALS1 and/or LGALS3 inhibitors

Read More

BeiGene presents new MAP4K1 inhibitors

Read More

New IL-10 variant proteins presented by Korean investigators

Read More

Funding supports Vaxess' work on mRNA-based single-dose, refrigeration-free vaccine patch

Read More

Elasmogen identifies novel anti-COVID-19 therapeutic candidates

Read More

Molecularly, skin disease shares much with development

Read More

FDA approves Lupkynis oral therapy for lupus nephritis

Read More

Hunterase ICV approved in Japan for MPS II

Read More

BirchBioMed reports phase II data on FS-2 for keloid scars

Read More

Novel GLP-1 and FGF-21 dual agonist D-1 shows potential for diabetes and NASH

Read More

Japanese approval for Yescarta for relapsed or refractory DLBCL

Read More

Antengene receives Chinese clearance for phase II/III study of selinexor for DLBCL

Read More

Phase III studies of faricimab in wet AMD meet primary endpoint

Read More

FDA approves Cabometyx plus Opdivo for advanced RCC

Read More

Neuregulin-1 beta 1 linked to early phase multiple sclerosis pathogenesis

Read More

Zydus reports phase IIb data on desidustat in patients with COVID-19

Read More

COLCORONA trial shows colchicine reduces risk of COVID-19-related complications

Read More

Japanese approval of Calquence for relapsed or refractory CLL

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 18, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 16, 2026
  • Brain with puzzle piece removed

    Gene replacement rescues autism-related phenotypes in mice

    BioWorld Science
    Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
  • Red blood cells, DNA

    For clonal hematopoiesis, epigenetics can be in driver’s seat

    BioWorld Science
    Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
  • Illustration of amyloid plaques in Alzheimer's disease

    Elixiron’s enrupatinib shows upbeat interim phase II AD results

    BioWorld
    Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing